
Site burden is now measured through satisfaction surveys, in-the-moment check-ins, and adoption patterns, but each method catches a different moment, and the gaps between them decide whether teams can act before burden becomes risk.
LabCorp has announced that Covance, its drug development business, is expanding its technology ecosystem to accelerate the adoption of decentralized clinical trials through an alliance with Medable. The Covance patient and site interface will be powered by Medable’s modular software platform, providing access to applications that will allow patients to participate in decentralized clinical trials.
For more information, click






